AT/ST, Department of Strategic Healthcare Development and Security, Skåne University Hospital, Lund, Sweden.
Anaesthesia and Intensive Care, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
J Intensive Care Med. 2024 Dec;39(12):1238-1249. doi: 10.1177/08850666241255328. Epub 2024 Jul 23.
The aim of this study was to investigate the development of fatigue and mental illness between 3 and 12 months after critical COVID-19 and explore risk factors for long-lasting symptoms. A prospective, multicenter COVID-19 study in southern Sweden, including adult patients (≥18 years) with rtPCR-confirmed COVID-19 requiring intensive care. Survivors were invited to a follow-up at 3 and 12 months, where patient-reported symptoms were assessed using the Modified Fatigue Impact Scale (MFIS), the Hospital Anxiety and Depression Scale (HADS) and the Posttraumatic Stress Disorder Checklist version 5 (PCL-5). The development between 3 and 12 months was described by changes in relation to statistical significance and suggested values for a minimally important difference (MID). Potential risk factors for long-lasting symptoms were analyzed by multivariable logistic regression. At the 3-month follow-up, 262 survivors (87%) participated, 215 (72%) returned at 12 months. Fatigue was reported by 50% versus 40%, with a significant improvement at 12 months (MFIS; median 38 vs. 33, < .001, MID ≥4). There were no significant differences in symptoms of mental illness between 3 and 12 months, with anxiety present in 33% versus 28%, depression in 30% versus 22%, and posttraumatic stress disorder in 17% versus 13%. A worse functional outcome and less sleep compared to before COVID-19 were risk factors for fatigue and mental illness at 12 months. Fatigue improved between 3 and 12 months but was still common. Symptoms of mental illness remained unchanged with anxiety being the most reported. A worse functional outcome and less sleep compared to before COVID-19 were identified as risk factors for reporting long-lasting symptoms.
本研究旨在探讨新冠肺炎重症患者在发病后 3 至 12 个月期间疲劳和精神疾病的发展情况,并探索长期症状的风险因素。这是一项在瑞典南部进行的前瞻性、多中心新冠肺炎研究,纳入了经 rtPCR 确诊需要重症监护的成年患者(≥18 岁)。幸存者在 3 个月和 12 个月时被邀请进行随访,使用改良疲劳影响量表(MFIS)、医院焦虑抑郁量表(HADS)和创伤后应激障碍检查表 5 版(PCL-5)评估患者报告的症状。通过与统计学意义相关的变化和最小有意义差异(MID)的建议值来描述 3 至 12 个月之间的发展情况。通过多变量逻辑回归分析潜在的长期症状风险因素。在 3 个月的随访中,有 262 名幸存者(87%)参与,215 名幸存者(72%)在 12 个月时返回。50%的人报告有疲劳感,而 40%的人报告有疲劳感,12 个月时疲劳感明显改善(MFIS;中位数 38 比 33,<.001,MID≥4)。3 个月和 12 个月之间精神疾病症状无显著差异,焦虑分别为 33%和 28%,抑郁分别为 30%和 22%,创伤后应激障碍分别为 17%和 13%。与新冠肺炎前相比,功能结局较差和睡眠较少是 12 个月时疲劳和精神疾病的风险因素。疲劳感在 3 至 12 个月之间有所改善,但仍很常见。精神疾病症状没有变化,焦虑是最常见的报告症状。与新冠肺炎前相比,功能结局较差和睡眠减少被确定为报告长期症状的风险因素。